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Hemangioblastomas consist of 10-20% neoplastic “stromal” cells within a vascular tumor cell mass of reactive pericytes,
endothelium and lymphocytes. Familial cases of central nervous system hemangioblastoma uniformly result from
mutations in the Von Hippel-Lindau (VHL) gene. In contrast, inactivation of VHL has been previously observed in only a
minority of sporadic hemangioblastomas, suggesting an alternative genetic etiology. We performed deep-coverage
DNA sequencing on 32 sporadic hemangioblastomas (whole exome discovery cohort n = 10, validation n = 22),
followed by analysis of clonality, copy number alteration, and somatic mutation. We identified somatic mutation,
loss of heterozygosity and/or deletion of VHL in 8 of 10 discovery cohort tumors. VHL inactivating events were
ultimately detected in 78% (25/32) of cases. No other gene was significantly mutated. Overall, deep-coverage
sequence analysis techniques uncovered VHL alterations within the neoplastic fraction of these tumors at higher
frequencies than previously reported. Our findings support the central role of VHL inactivation in the molecular
pathogenesis of both familial and sporadic hemangioblastomas.
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Hemangioblastomas comprise 1–2.5% of primary intracra-
nial and 7-10% of spinal cord tumors, with a benign path-
ology notable for neoplastic “stromal” cells embedded in a
dense network of vascular channels [1]. These tumors are
largely diploid with few chromosomal abnormalities [2,3],
and have served as the prototypic lesions in the study of
genomic drivers of hypoxia-mediated metabolism in cancer
[4]. Approximately 25% of hemangioblastomas are a result
of Von Hippel-Lindau (VHL) disease, which is inherited
in an autosomal dominant manner through a germline
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unless otherwise stated.on chromosome 3, with subsequent inactivation of the
second allele by somatic mutation or gene loss in the neo-
plastic “stromal” cell. The clinical spectrum of VHL disease
includes other neoplastic lesions, including retinal angioma-
tosis, pheochromocytoma and clear cell renal carcinoma.
Approximately 75% of hemangioblastomas are sporadic.
VHL somatic mutations have been clearly identified in a
fraction of sporadic tumors [2-10]. However, unlike in
familial VHL disease, prior studies have indicated that the
majority of sporadic hemangioblastomas do not have iden-
tifiable germline or somatic alterations in VHL (Table 1).
This discrepancy stands in contrast to recent whole
genome characterization of clear cell renal carcinomas,
which have somatic mutations in the VHL gene in >80% of
samples [11,12], focal deletion by loss of chromosome
3p26.1 in >90% [13], or epigenetic silencing by promoter
methylation in 7% [13].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Findings from prior studies analyzing sporadic hemangioblastomas for somatic mutations, loss of heterozygosity or deletion of VHL
Somatic mutation Loss of heterozygosity Deletion Biallelic VHL
inactivation (%)Reference Patients Method Positive
cases
Rate of somatic
mutation (%)
Method Positive cases Rate of
LOH (%)
Method Positive cases Rate of
deletion (%)
Kanno et al. [6] 13 Sanger 3/13 23 NA NA NA NA NA NA NA
Oberstrass et al. [7] 18 Sanger 8/18 44 NA NA NA NA NA NA NA
Tse et al. [5] 5 Sanger 2/5 40 polymorphic
markers
1/2 50 NA NA NA 10
Olschwang et al. [8] 18 Sanger 2/18 11 NA NA NA NA NA NA NA
Lee et al. [9] 20 Sanger 2/20 10 polymorphic
markers
10/19 53 NA NA NA 11
Glasker et al. [3] 13 Sanger 3/13 23 polymorphic
markers
5/13 38 NA NA NA 8
Gijtenbeek et al. [2] 16 Sanger 5/16 31 NA NA NA CGH 11/16 69 19
Lemeta et al. [10] 11 NA NA NA polymorphic
markers
11/11 100 CGH 2/11 18 18
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tween the reported frequency of mutations in VHL between
familial and sporadic hemangioblastomas. The first explan-
ation is that sporadic cases of hemangioblastoma may
develop via alterations in genes involved in hypoxia-sensing
pathways other than VHL itself that also result in a
histologically-identical phenotype of exuberant angiogenesis.
A candidate gene for such an alteration is TCEB1, which
encodes the required VHL binding partner elongin C and,
in the recent genomic sequencing of clear cell renal carcin-
oma was found to be somatically mutated in the minority of
cases that do not harbor VHL mutations [14]. A second
explanation is that prior bulk sequencing techniques were
technically limited in capturing the full extent of VHL inacti-
vation. Neoplastic “stromal” cells comprise roughly 10-20%
of the hemangioblastoma tumor cell mass with the remain-
der consisting of pericytes, vascular endothelium and other
nucleated cells, such as lymphocytes, that are present in the
vascular channels [15]. Given the relatively low purity of
neoplastic cells, previous studies may not have detected the
entire spectrum of alterations in VHL.
The emergence of next generation sequencing technolo-
gies has rapidly accelerated the discovery of somatic
alterations in cancer genes, by exploiting greater depth-of-
coverage to increase the sensitivity of detection within low
purity samples [13,16-22]. Application of these techniques
to hemangioblastomas can comprehensively examine the
role of VHL across the spectrum of this disease. In addition,
whether hemangioblastomas form from an embryologically
arrested “hemangioblast” stem cell that subsequently differ-
entiates into the discrete constituent cell types that support
the architecture of this vascular tumor [1,23-25] is unclear.
While developmental studies have shown a common pre-
cursor of the differentiated cell types (endothelial, stromal)
found in the hemangioblastoma cell mass, whether neo-
plastic cells contribute to these different populations was
not well-characterized. By analyzing the extent of genomic
alterations and their subclonal and clonal status within the
tumor mass of sporadic hemangioblastomas, this issue can
be addressed. In this study, we characterize sporadic
hemangioblastomas of cerebellum and spinal cord by whole
exome sequencing and deep-coverage sequence analysis.
Materials and methods
Sample acquisition
This study was approved by the Institutional Review
Board at the hospitals providing specimens. Written
informed consent was obtained for all samples undergoing
whole exome sequencing. The discovery and validation
cohorts of sporadic hemangioblastomas involving the
cerebellum and spinal cord were obtained from patients
treated at Massachusetts General Hospital (MGH, Boston
MA), Brigham and Women’s Hospital (BWH, Boston MA),
and Seoul National University (South Korea). Patients wereidentified as likely sporadic hemangioblastomas based on
(1) prior testing that was negative for germline VHL muta-
tions by sequencing of the coding regions (exons 1–3), (2)
lack of family history of hemangioblastomas or VHL dis-
ease, and/or (3) lack of other stigmata of VHL disease, such
as renal cancer, pheochromocytoma, or retinal angiomas.
Pathology was verified by the Departments of Pathology at
MGH and BWH (DNL, SS and MA) and tumor rich
areas were microdissected.
Tumor sequencing
DNA was extracted from FFPE tumor specimens and
matching peripheral blood samples using standard tech-
niques (QIAamp, Qiagen) and quantified by PicoGreen dye
(Invitrogen). Whole exome sequencing was performed
by hybrid capture and next-generation sequencing as
described previously [26]. In brief, DNA was fragmented by
sonication (Covaris Inc., Woburn, MA) to 150 bp and
further purified using Agencourt AMPure XP beads. 50 ng
of size-selected DNA was then ligated to specific adaptors
during library preparation (Illumina TruSeq, Illumina Inc.,
San Diego, CA). Each library was made with sample-
specific barcodes and quantified by quantitative PCR (Kapa
Biosystems, Inc., Woburn, MA), and two libraries were
pooled to a total of 500 ng for exome enrichment using the
Agilent SureSelect hybrid capture kit (Whole Exome_v1.1;
Agilent Technologies, Santa Clara, CA). Several captures
were pooled further and sequenced in one or more lanes to
a final equivalent of two exomes per lane on a HiSeq 2500
system (Illumina Inc, San Diego, CA).
The validation cohort was sequenced for 560 cancer-
associated genes and 39 translocations previously impli-
cated in cancer (Additional file 1: Table S1). Briefly, DNA
was sonicated to achieve an average fragment size of
250 bp, size selected and barcoded. Multiplexed pools were
hybridized with biotinylated baits (Agilent SureSelect)
designed to capture exonic sequences, including those of
VHL and ARID1B. The captures were sequenced on the
Illumina HiSeq 2500 in Rapid Run Mode.
Separately, Sanger sequencing of the TCEB1 Tyr79Cys
hotspot, and the promoter and exon 1 of VHL, was per-
formed on PCR amplified products from tumor genomic
DNA. Chromatograms were manually reviewed to evaluate
for the presence of somatic mutations, which may be
represented as a minor allele.
Mutation analysis
Somatic variant, germline variant, and small deletions and
insertion calling was performed within the Firehose envir-
onment at the Broad Institute with the previously published
MuTect, MapReduce, and Indelocator algorithms [27-30].
Pindel, an algorithm for detecting insertions and deletions
(indels) [31], was used to detect indels in the coding regions
of VHL. Because the samples were all obtained from
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mens, we applied a filtering algorithm to reduce the
number of artifactual mutations introduced by FFPE [32].
The FFPE filter consists of two steps. First, the filter esti-
mates the component of total sequencing error rate due to
FFPE artifacts in a CpG island by scanning all reference C
(or G) sites counting sites sequenced as T (or A) in the two
possible read pair orientations. Second, the orientation of
each C >T (or G >A) mutation is compared to a model of
balanced read pair orientation (binomial with p = 0.5: no
artifact) and a biased orientation characteristic of FFPE
artifacts (binomial with p = 0.96), as FFPE-induced artifacts
affect one of the DNA strands. The filter removes muta-
tions consistent with the FFPE orientation bias to the
degree where less than 1% of the surviving mutations in a
given sample are consistent with FFPE artifacts. Signifi-
cance of mutated genes was determined by MutSigCV [33].
Copy number and rearrangement analysis
Segmented copy data was obtained using copy number ra-
tios. These were calculated as the ratio of tumor read depth
to the average read depth observed in a panel of normal
samples. Subsequently we converted the copy ratio data
to allelic ratio, which allows for detection of copy neutral
LOH and gives another constraint on copy number alter-
ations. ABSOLUTE [22] was used to estimate sample
purity and ploidy and then calculate cancer cell fraction
(inferred percentage of neoplastic nuclei that harbor a
given mutation) and cell copy number of mutations and
local DNA copy changes. Rearrangements were determined
by the dRanger and BreakPointer algorithms [34].
Loss of heterozygosity analysis of validation cohort
To assess whether VHL in our validation cohort was de-
leted or in copy neutral loss of heterozygosity, we exam-
ined the distribution of allele fractions of heterozygous
mutations in the mix of reported somatic and germline
variants. In a diploid state (ploidy = 2) germline hetero-
zygous sites should be represented by 50% allele fraction.
When samples gain or lose a copy, the allele fraction of
those sites will shift in relationship to the purity of the
tumor. In order to determine the copy state of each sam-
ple we identified peaks in the probability density function
(pdf) of allele fractions:
pdf Chr3pð Þ ¼
X
m
pdf af ; alt mð Þ þ 1; ref mð Þ þ 1ð Þ
Where af is the true allele fraction between 0 and 1, and
alt is the alternate allele counts, ref is the reference allele
count, and m is each single nucleotide variant detected
along chromosome 3p. Samples demonstrating allelic frac-
tions with bimodal distributions were called positive for a
deletion or copy neutral loss of heterozygosity.For samples demonstrating allelic shift, tumor purity
(PT) was further estimated from the allele fraction of the
upper allele (χA) in the two following scenarios.
(1)if the LOH event represents a copy neutral event, then
the tumor purity (PT) is given by the following
equation:
PT ¼ 2  χA
(2)if the LOH event was a result of haploidization, then
the tumor purity is given by:
PT ¼ 2  χA−1
χA
Immunohistochemistry
Five micron sections of the FFPE specimens from the
discovery cohort were prepared and stained for HIF1-α
(NB100-131, Novus Biologicals), VEGF (SC-152, Santa
Cruz Biotechnology), or PDGFR-β (AB32570, Abcam)
by protocols described in the product data sheets. IHC
was reviewed and scored by MPH.
Results
We performed whole exome sequencing (WES) of 10
sporadic hemangioblastomas for our discovery cohort and
targeted sequencing of 22 sporadic hemangioblastomas
for our validation cohort. Estimation of neoplastic stromal
cell content was 10-30% at pathology review (Additional
file 2: Figure S1). The average age of the patients in the
combined cohorts was 53.3 years with 23 tumors resected
from the cerebellum and 9 from the spinal cord (Table 2).
WES of germline DNA from the discovery cohort did not
reveal any VHL mutations, indicating that these pa-
tients do not have VHL disease and that the tumors we
evaluated are bona fide sporadic hemangioblastomas.
The exomes of tumor specimens in the discovery cohort
were covered at a mean depth of 116× (Additional file 1:
Table S2). We did not detect any rearrangements in the
discovery cohort using previously reported algorithms,
which can detect events that occur close to exons [34].
Copy number analysis of the WES data revealed recur-
rent loss of chromosome 3, but otherwise the genomes of
tumors in the discovery cohort were diploid (Figure 1). By
combining coverage ratio and allelic data to determine
regions of somatic copy change and copy neutral loss
of heterozygosity (copy neutral-LOH), we found focal
hemizygous deletions of chromosome 3p resulting in
loss of the VHL locus in 3 samples and hemizygous de-
letion of the entire chromosome 3p arm in 4 samples
of the discovery cohort (Additional file 3: Figure S2,
Additional file 1: Table S3). One sample was found to
Table 2 Baseline clinical characteristics of discovery and
validation cohorts of sporadic hemangioblastomas
sequenced in this study
Discovery (n = 10) Validation (n = 22)
Average Age (IQR) 52 (44–61) 54 (44–63)
Location
Cerebellum 8 15
Spinal cord 2 7
Gender
Male 7 9
Female 3 13
Prior VHL testing 1 5
Additional VHL-related lesions 0 0
Interquartile range (IQR) for age of patients is represented in parentheses.
Patients who had undergone prior clinical testing for germline VHL mutations
are listed. No patients included in either cohort were noted to have canonical
VHL-related lesions, including retinal hemangioblastomas, pancreatic lesions,
pheochromocytomas, endolymphatic sac tumors, renal cysts or clear cell renal
carcinoma.
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additional sample was found to have a copy neutral
LOH of the entire chromosome 3p arm. Deletion of
chromosome 8 was noted in 2 specimens and deletion
of chromosome 6 in one specimen.
To identify somatic mutations in the WES data, a filter
was first applied to exclude artifact mutations introduced
by the processing of formalin-fixed, paraffin-embedded
(FFPE) specimens, which are characterized by artificially
induced C > T [32]. These artifact mutations are distinct
from real CpG > TpG mutations, which dominate in most
cancers. The FFPE filter accordingly removed 10 spurious
mutations (Additional file 4: Figure S3).
The sequence data was then post-processed with MuTect
[27] to identify true somatic mutations. The average
overall mutation rate was 1.5/Mb with a total of 398 non-
synonymous mutations and 118 synonymous muta-
tions detected among the 10 samples (Additional file 1:
Table S4). In comparison to other adult solid tumors,
sporadic hemangioblastomas have a relatively low somatic
mutation rate (Figure 2a), but one that is similar to other
intracranial neoplasms with a tendency to local recurrence
but not widespread dissemination, such as meningiomas
(1.6/Mb) [26,35] and craniopharyngiomas (0.9/Mb) [19].
A total of 377 genes were found to have at least one
non-synonymous mutation in the discovery set (Additional
file 1: Table S4). Of these, VHL was mutated in 5 samples
with an allele fraction ranging from 18-21% and cancer cell
fraction from 76-100%, suggesting a clonal somatic muta-
tion carried by the subpopulation of neoplastic “stromal”
cells. VHL was the only gene found as statistically signifi-
cant with respect to the false discovery rate by MutSigCV
[27] (Figure 2b, q < 0.1), suggesting that no other gene is
mutated at a similar rate.Because exon 1 of VHL was covered at a lower mean
depth (13×) than exons 2 (213×) and 3 (51×) (Figure 2b),
the promoter region and exon 1 were separately PCR amp-
lified and Sanger sequenced for the four specimens that
did not demonstrate evidence for biallelic VHL inacti-
vation. None of these specimens, for which exon 1 was
initially covered at a mean of 7.4×, demonstrated som-
atic mutations in the promoter region or exon 1 of VHL
by Sanger sequencing, although this method is not highly
sensitive for detection of mutations with low allelic frac-
tions. Of note, two missense mutations in ARID1B were
identified in two separate hemangioblastomas, at amino
acid positions 647 and 651, with predicted allelic fractions
of 2-6% and cancer cell fraction of 8-32%, suggesting
subclonality.
When mutations, deletions or LOH events involving
the VHL locus are taken together, the discovery cohort
of sporadic hemangioblastomas demonstrate biallelic in-
activation of VHL in 6 of 10 cases and inactivation of at
least a single allele of VHL in 8 of 10 cases (Figure 3).
The validation cohort consisted of 22 sporadic heman-
gioblastomas, for which the exons of 560 genes (including
VHL and ARID1B) and 39 translocations previously impli-
cated in cancer were sequenced at an average depth of
182x. The validation cohort revealed LOH of chromosome
3p in 15 of the 22 samples (Additional file 5: Figure S4).
Tumor purity was estimated for the validation specimen
demonstrating LOH and ranged from 8-57% (Additional
file 1: Table S5). VHL was sequenced at a mean depth of
87× in this cohort and eleven specimens were found to
have non-synonymous mutations in VHL (Additional
file 1: Table S6). One of these specimens was noted to
have a frame shift 22-nucleotide tandem duplication in
exon 3 within 8 codons of the stop codon. Of note, while
the validation specimens were selected as representing
sporadic hemangioblastomas by clinical information and
germline testing for most, it is possible that up to 10% of
these patients without matched blood may have germline
VHL mutations [7,8]. Of specimens in the validation
cohort that were found to have a non-synonymous mu-
tation in VHL, 82% also had LOH (Figure 4). No non-
synonymous mutations in ARID1B were detected in the
validation set. In addition, no TCEB1 Tyr79Cys muta-
tions were detected in any of the 32 hemangioblasto-
mas in this study.
Prior studies have raised the possibility that hemangio-
blastomas arise from an embryologically arrested heman-
gioblast capable of differentiating into any of the cell
types that comprise this vascular network, including peri-
cytes, vascular endothelium, and even erythrocyte islands
[1,23-25,36,37]. To assess the tumor cell fraction, we used
ABSOLUTE, an algorithm which estimates tumor purity
and ploidy allowing for calculation of cell copy number
and cancer cell fraction of local DNA segments and
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for analyzing craniopharyngiomas, in which the fraction of
neoplastic cells within the tumor bulk can be <10% [19].
Tumor purity of the discovery cohort determined by
ABSOLUTE ranged from 9-49% (median 33%) (Additional
file 1: Table S2), which corresponds to the neoplastic cell
content of sporadic hemangioblastomas (Figure 5). This
intercellular genomic heterogeneity suggests that the
majority of nucleated cells in the tumor mass do not
arise from a common ancestral clone, supporting the
model that the tumor mass histology is a consequence
of reactive angiogenesis resulting from paracrine sig-
naling mediated by the VHL-deficient HIF1α-expressing
“stromal” cells.Discussion
VHL mutations have been previously detected in sporadic
hemangioblastomas [2-10]. Our study is the first to com-
prehensively set an upper bound on the frequency of other
alterations in hemangioblastoma formation, and further
confirm that VHL alterations can be detected in the vast
majority of hemangioblastomas, establishing VHL inacti-
vation as the central event in formation of this tumor.
Based on the implications of prior work, these findings
were one of the possible anticipated results in this proto-
typic tumor type, and were facilitated by next generation
sequencing techniques. In addition, utilization of this tech-
nology allowed for quantification of allelic frequency, re-
vealing the cell non-autonomous role of VHL-inactivated
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Figure 2 Sporadic hemangioblastomas demonstrate low somatic mutation rates, but have recurrent mutations in VHL. (a) Plot of the
number of nonsynonymous mutations per megabase in hemangioblastomas in comparison to other primary tumors of the central nervous system,
including medulloblastoma, craniopharyngioma, low grade glioma (LGG) and glioblastoma (GBM) [18]. For comparison, the mutation rate of
lung adenocarcinoma and melanoma are displayed [24]. Each dot in this plot corresponds to a matched tumor-normal pair. The vertical position indicates
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tumor cell mass via recruitment of intermixed normal
endothelial cells.
Biallelic VHL inactivation in hemangioblastoma results
in insufficient degradation of HIF-1α, which then results
in the inappropriate transcription of effectors normally
expressed in hypoxic states, such as vascular endothelial
growth factor (VEGF) or platelet derived growth factor B
(PDGF B) [38]. Accordingly, the tumor cell mass is com-
posed largely of non-neoplastic endothelial cells and
surrounding pericytes, with only a minor component con-
sisting of neoplastic “stromal” cells that actually bear driver
mutations. The process of tumorigenesis is thus driven by
a subpopulation of neoplastic cells that recruit and interact
with diverse cellular types to form the tumor mass [39,40].
Genomic analyses that do not sufficiently account for
such cell-type purity issues can incompletely characterize
the spectrum of alterations within the neoplastic cellularcompartment. Sporadic hemangioblastomas therefore
offered an enticing opportunity to use the most current
analytics in cancer genomics to uncover cryptic driver al-
terations, which may be present in only a minor subpopu-
lation of the overall tumor mass, evading detection by
prior bulk tissue analyses.
As predicted by the benign clinico-pathologic features,
hemangioblastomas were notable for a relatively low fre-
quency of mutations. Within this context of infrequent mu-
tations and copy number alterations, we found a markedly
high prevalence of recurrent somatic mutations (50%) and
LOH of the gene locus on chromosome 3p (72%). Together,
these alterations account for biallelic inactivation of
VHL in 47% and an inactivating alteration in at least
one allele in 78% of sporadic hemangioblastomas. We
detected these alterations in specimens with tumor cell
fractions as low as 9%. It is possible that we could have
captured an even higher prevalence of VHL inactivation
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across VHL in its entirety.
Prior studies have reported the presence of mutations
in VHL in 10 to 44% of sporadic hemangioblastoma [4].
The frequency of aneuploidy of chromosome 3 has ranged
from 18 to 69% in these sporadic tumors [2,3]. One study
identified concurrent somatic mutation and LOH of VHL
in only 1 of 13 sporadic hemangioblastomas [3] and an-
other study identified missense mutations with deletion
of VHL by comparative genomic hybridization in only 2
of 16 sporadic hemangioblastomas [2]. This is likely a
consequence of lower VHL mutant allele fractions con-
fined to the neoplastic “stromal” cells in sporadic heman-
gioblastomas, as compared to familial tumors that are
characterized by heterozygous germline VHL alterations.Mutations in ARID1B, which behaves as a tumor sup-
pressor in other cancers [41-44], were detected in this
study in 20% of the discovery cohort, a level that did not
reach statistical significance by our analysis. Furthermore,
the mutations were present with allelic fractions of only 2-
6% and these lesions were found to be subclonal. Further
analysis is needed to determine whether such subclonal
variants are functionally important in supporting the
development of sporadic hemangioblastomas [45,46].
VHL inactivation in the pathogenesis of sporadic heman-
gioblastoma mirrors the VHL alterations seen in benign
renal cysts, which may serve as precursors of clear cell
renal cancer [47]. These cysts are notable for biallelic
VHL inactivation in renal tubular epithelial cells; whereas,
clear cell renal cancer is additionally characterized by
Shankar et al. Acta Neuropathologica Communications  (2014) 2:2 Page 10 of 12mutations in genes involved in the PTEN-mTOR pathway
[13,14]. Similar to benign renal cysts, hemangioblastomas
rarely demonstrate aggressive malignant features, and
we did not detect additional clonal genetic drivers in
hemangioblastomas, including other candidate genomic
loci on chromosome 3p of BAP1, SETD2, and PBRM1 im-
plicated in clear cell renal carcinoma.
The analysis of tumor purity by ABSOLUTE also dem-
onstrates that the extent of VHL inactivation in these
tumors parallels “stromal” cell content estimated by IHC,
rather than representing a homogenous genome that would
characterize a tumor cell mass entirely derived from an
ancestral hemangioblast clone. This important distinction
lends further support to the model that stromal cells are
genetically unique in VHL deficiency and stimulate react-
ive angiogenesis by recruiting normal endothelial cells via
pseudo-hypoxia mediated paracrine signaling. This model
contrasts with the alternate proposed pathway of an em-
bryologically arrested “hemangioblast” ancestral clone that
trans-differentiates into the various cell types contained in
the tumor [24,25,36].
In summary, we find that inactivation of VHL is highly
recurrent and characteristic of the majority of sporadic
hemangioblastomas. In addition, we do not detect other
common recurrent somatic mutations in these tumors.
These data therefore confirm the central role of VHL in-
activation in all hemangioblastomas, suggesting that treat-
ment strategies for both familial and sporadic cases could
be uniformly considered, as VHL loss in the neoplastic
subpopulation likely orchestrates the architecture of these
tumors. For example, VEGF inhibitors have been used in
cases of multifocal familial hemangioblastomas with treat-
ment responses [48,49]; their use in surgically-challenging
sporadic disease should be considered. Advances in deep-
coverage sequence analysis have thus resulted in a more
complete understanding of the molecular basis of this ca-
nonical cancer type, and hold promise for the discovery of
similarly cryptic drivers of tumorigenesis in other cancers
with complex and diverse cellular composition.
Conclusions
In this study, we performed whole exome sequencing of
matched tumor-normal specimens of sporadic hemangio-
blastoma and found that VHL inactivation is more highly
prevalent in this disease process than previously noted
and that no other gene alteration was identified at a
statistically significant level in these tumors. High depth
sequencing was required to unmask the low allelic fraction
of VHL mutations and copy number alterations found in
the neoplastic “stromal” cells, which are present only in
a fraction of cells comprising the overall tumor mass.
The central role of VHL in the formation of sporadic
hemangioblastomas suggests that the approach to these
tumors can be universally considered as a single entitytogether with familial cases, which arise as a result of
VHL disease.Additional files
Additional file 1: Table S1. List of exomes and translocations that were
sequenced in the validation cohort. Coding regions of 560 genes and 39
translocations previously implicated in cancer were targeted in the analysis
of this cohort. Table S2. Mean target coverage data in discovery cohort of
tumor and matched normal specimen. Tumor purity represented as a
percentage was estimated by ABSOLUTE. Table S3. Allelic copy ratio of
sequenced exome segments in discovery cohort. Table S4. Composite
table of somatic mutations detected in discovery cohort by whole exome
sequencing. CCF column indicates fraction of neoplastic cells that harbor
the mutation as determined by ABSOLUTE. Table S5. Loss of heterozygosity
analysis of validation cohort. As described in Materials and methods, tumor
purity was estimated from the fraction of the upper allele in the two
following scenarios: (1) if the LOH event represents a copy neutral event or
(2) if the LOH event was a result of haploidization. Table S6. Composite
table of the somatic mutations detected in the validation cohort by
targeted sequencing of 560 cancer associated genes (OncoPanel).
Additional file 2: Figure S1. Representative histopathology of sporadic
hemangioblastoma sequenced in this study. Hematoxylin and eosin stain
of sporadic hemangioblastoma at 200× magnification (scale bar = 50 μm)
reveals cellular heterogeneity consisting of pericytes, vascular
endothelium, blood cells, and the neoplastic “stromal” cells which are
cells with foamy cytoplasm representing 10-30% of the overall mass.
Additional file 3: Figure S2. Segmentation of coverage and allelic data
reveals recurrent deletion and LOH (blue) of the VHL locus in the discovery
cohort. Darker shades of blue indicate increased copy loss. Each row
represents a sample within the discovery cohort. The VHL locus along
chromosome 3p is indicated by the red arrow.
Additional file 4: Figure S3. Two dimension histogram of SNV read
strand orientation bias (i_ffpe_F) vs. alternate allele counts (alt counts) in
the C > T (or complement G > A) mutation mode. The color code on the
right indicates the number of mutations falling into a given bin. The
histogram at the bottom is a projection of all mutation to the i_ffpe_F
axis and the histogram along the left is a projection onto alt allele
counts. Real mutations are expected to have a symmetric distribution
(binomial distribution with probablility 0.5 at each alt count) but there is
a clear bias toward i_ffpe_F values approaching 1.0, particularly at the
lowest allele counts. This bias is a result of the single strand damage
characteristic of FFPE. The filter removes mutations occurring in the lower
right section, with a threshold optimized to leave at most one percent of
the surviving mutations arising from FFPE artifact [32].
Additional file 5: Figure S4. Sporadic hemangioblastomas in the
validation cohort display recurrent loss of heterozygosity of chromosome
3p. The frequency of allele fractions of mutations on chromosome 3p were
plotted and loss of heterozygosity was identified in 15 samples where allelic
shift (vertical red and blue lines) was noted from the expected distribution
centered at 0.5 (vertical black line).Competing interests
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